

**Paper: “Patents and the Global Diffusion of New Drugs”**

**Disclosure Statement: Iain M. Cockburn**

1. Financial support for this research is acknowledged in the paper.
2. Other financial support from potentially interested parties received since 2011:  
Consultant fees greater than \$10,000 in total from
  - a. Sun Pharmaceuticals
  - b. Watson Pharmaceuticals
  - c. Eli Lilly
  - d. GlaxoSmithKline
  - e. Amgen
  - f. Volcano Corporation
  - g. Sanofi-Aventis
  - h. Merck
  - i. Gilead Sciences
3. Board member of Acceleration Biopharmaceuticals Inc until 2012.
4. No relevant disclosures for close relatives or spouse.
5. IMS Health Inc. reviewed the manuscript for unauthorized disclosure of any of their proprietary information, but not regarding content or conclusions.

**Disclosure Statement: Mark Shankerman**

1. Sources of financial support for this research are acknowledged in the paper. The sources are the World Bank, the Brookings Institution, and the National Foreign Trade Council Foundation in Washington, D.C.
2. No financial support received since 2011 from any interested parties.
3. No position in relevant organizations.
4. No relevant disclosures for close relatives or spouse.

5. IMS Health Inc. reviewed the manuscript for unauthorized disclosure of any of their proprietary information only, but not for anything regarding content or conclusions.

**Disclosure Statement: Jean Lanjouw**

1. Sources of financial support for this research are acknowledged in the paper.
2. No financial support received since 2011 from any interested parties. (Deceased.)
3. No position in relevant organizations. (Deceased.)
4. No relevant disclosures for close relatives or spouse.
5. IMS Health Inc. reviewed the manuscript for unauthorized disclosure of any of their proprietary information only, but not for anything regarding content or conclusions.